Education
About Us
Working with TipRanks
Follow Us
Zealand Pharma (ZLDPF)
OTHER OTC:ZLDPF
Total Valuation
Zealand Pharma has a market cap or net worth of $4.44B. The enterprise value is $9.26B.
Market Cap$4.44B
Enterprise Value$9.26B
Share Statistics
Zealand Pharma has 71,515,045 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,515,045
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Zealand Pharma’s return on equity (ROE) is 0.44 and return on invested capital (ROIC) is 41.71%.
Return on Equity (ROE)0.44
Return on Assets (ROA)0.39
Return on Invested Capital (ROIC)41.71%
Return on Capital Employed (ROCE)0.45
Revenue Per Employee23.93M
Profits Per Employee16.77M
Employee Count385
Asset Turnover0.56
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Zealand Pharma is 4.3. Zealand Pharma’s PEG ratio is ―.
PE Ratio4.3
PS Ratio0.00
PB Ratio0.00
Price to Fair Value2.22
Price to FCF0.00
Price to Operating Cash Flow4.25
PEG Ratio―
Income Statement
In the last 12 months, Zealand Pharma had revenue of 9.21B and earned 6.46B in profits. Earnings per share was 91.56.
Revenue9.21B
Gross Profit9.19B
Operating Income7.16B
Pretax Income7.00B
Net Income6.46B
EBITDA7.18B
Earnings Per Share (EPS)91.56
Cash Flow
In the last 12 months, operating cash flow was 6.53B and capital expenditures -35.98M, giving a free cash flow of 6.50B billion.
Operating Cash Flow6.53B
Free Cash Flow6.50B
Free Cash Flow per Share90.83
Dividends & Yields
Zealand Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.52
52-Week Price Change-37.34%
50-Day Moving Average68.84
200-Day Moving Average67.64
Relative Strength Index (RSI)42.96
Average Volume (3m)135.00
Important Dates
Zealand Pharma upcoming earnings date is May 7, 2026, TBA (Confirmed).
Last Earnings DateFeb 19, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Zealand Pharma as a current ratio of 23.57, with Debt / Equity ratio of 3.28%
Current Ratio23.57
Quick Ratio23.57
Debt to Market Cap0.01
Net Debt to EBITDA-0.57
Interest Coverage Ratio189.81
Taxes
In the past 12 months, Zealand Pharma has paid 546.06M in taxes.
Income Tax546.06M
Effective Tax Rate0.08
Enterprise Valuation
Zealand Pharma EV to EBITDA ratio is 4.01, with an EV/FCF ratio of 4.43.
EV to Sales3.12
EV to EBITDA4.01
EV to Free Cash Flow4.43
EV to Operating Cash Flow4.41
Balance Sheet
Zealand Pharma has $15.11B in cash and marketable securities with $394.64M in debt, giving a net cash position of $14.62B billion.
Cash & Marketable Securities$15.11B
Total Debt$394.64M
Net Cash$14.62B
Net Cash Per Share$204.47
Tangible Book Value Per Share$209.72
Margins
Gross margin is 99.83%, with operating margin of 77.66%, and net profit margin of 70.05%.
Gross Margin99.83%
Operating Margin77.66%
Pretax Margin75.98%
Net Profit Margin70.05%
EBITDA Margin77.95%
EBIT Margin77.66%
Analyst Forecast
The average price target for Zealand Pharma is $120.09, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$120.09
Price Target Upside91.65% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast―